指南与共识免疫规划传染病防控与疫情报告卫生政策与健康促进

ACIP关于使用辉瑞-BioNTech COVID-19疫苗的临时建议——美国,2020年12月

The Advisory Committee on Immunization Practices' Interim Recommendation for Use of Pfizer-BioNTech COVID-19 Vaccine - United States, December 2020.
指南 / 共识 · MMWR Morb Mortal Wkly Rep · 2020-12-18

2020年12月11日FDA对辉瑞-BioNTech COVID-19 mRNA疫苗(BNT162b2)发布紧急使用授权,12月12日ACIP发布临时建议,推荐≥16岁人群接种该疫苗预防COVID-19,采用GRADE方法及EtR框架形成推荐,并将随新信息更新。

要点

  • ACIP临时推荐≥16岁人群使用辉瑞-BioNTech COVID-19疫苗预防COVID-19。
  • 该疫苗接种程序为2剂,每剂30 μg(0.3 mL),肌内注射,间隔3周。
  • 推荐应结合ACIP关于初始疫苗供应分配的临时建议实施。

核心结论

  • ACIP临时推荐≥16岁人群使用辉瑞-BioNTech COVID-19疫苗预防COVID-19。

研究设计与样本

  • ACIP采用GRADE方法和EtR框架形成临时推荐,基于FDA紧急使用授权。

主要发现

  • 辉瑞-BioNTech COVID-19疫苗为脂质纳米颗粒配方的核苷修饰mRNA疫苗,编码SARS-CoV-2融合前刺突糖蛋白。
  • 疫苗接种为2剂,每剂30 μg(0.3 mL),肌内注射,间隔3周。

关键数值与推荐

  • 推荐人群为≥16岁者,用于预防COVID-19。
  • 推荐应结合ACIP关于初始COVID-19疫苗供应分配的临时建议实施。

临床怎么用

  • 对≥16岁人群按2剂、间隔3周肌内接种辉瑞-BioNTech COVID-19疫苗。
  • 实施接种时应同时参考ACIP初始供应分配建议。

局限性

  • 该推荐为临时建议,将随更多信息更新。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

On December 11, 2020, the Food and Drug Administration (FDA) issued an Emergency Use Authorization (EUA) for the Pfizer-BioNTech COVID-19 (BNT162b2) vaccine (Pfizer, Inc; Philadelphia, Pennsylvania), a lipid nanoparticle-formulated, nucleoside-modified mRNA vaccine encoding the prefusion spike glycoprotein of SARS-CoV-2, the virus that causes coronavirus disease 2019 (COVID-19) (1). Vaccination with the Pfizer-BioNTech COVID-19 vaccine consists of 2 doses (30 μg, 0.3 mL each) administered intramuscularly, 3 weeks apart. On December 12, 2020, the Advisory Committee on Immunization Practices (ACIP) issued an interim recommendation* for use of the Pfizer-BioNTech COVID-19 vaccine in persons aged ≥16 years for the prevention of COVID-19. To guide its deliberations regarding the vaccine, ACIP employed the Evidence to Recommendation (EtR) Framework,† using the Grading of Recommendations, Assessment, Development and Evaluation (GRADE) approach.§ The recommendation for the Pfizer-BioNTech COVID-19 vaccine should be implemented in conjunction with ACIP's interim recommendation for allocating initial supplies of COVID-19 vaccines (2). The ACIP recommendation for the use of the Pfizer-BioNTech COVID-19 vaccine under EUA is interim and will be updated as additional information becomes available.

来源:MMWR Morb Mortal Wkly Rep,查看原文。版权归原作者所有。

引用

  1. Oliver SE, Gargano JW, Marin M, et al. The Advisory Committee on Immunization Practices' Interim Recommendation for Use of Pfizer-BioNTech COVID-19 Vaccine - United States, December 2020. MMWR Morb Mortal Wkly Rep. 2020. PMID: 33332292. doi:10.15585/mmwr.mm6950e2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。